Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2005

View Archived Issues

Targeting of HCV IRES to effectively treat chronic hepatitis C virus infection

NS-187: dual Bcr-Abl/Lyn inhibitor

Brivaracetam displays potent anticonvulsant effects in a model of SSSE

Caspase-1 inhibitors attenuate seizures by blocking brain IL-1beta

GlaxoSmithKline completes acquisition of ID Biomedical

AstraZeneca to develop Protherics' CytoFab

Ono and Dainippon Sumitomo sign new agreement for limaprost alfadex

New inhibitor of factor VIIa prevents tissue factor-initiated thrombus formation

Shionogi launches Avelox in Japan

ZymoGenetics profiles R&D programs

Cymbalta to be filed for generalized anxiety disorder in 2006

Canadian clearance for first-in-man study of PPL-100 for drug-resistant HIV

CK-1827452 selected as development candidate for chronic heart failure

Phase III ACUITY study of Angiomax completes enrollment

Treatment begins in phase III study of DX-88 for hereditary angioedema

Prevention and treatment of mammary tumors with a combination of SERM plus rexinoid

PSN-9301 effective in reducing glucose levels

Patient-specific cancer vaccines discussed at hematology meeting

ISA-247 shows long-term safety in patients with moderate to severe psoriasis

NG2-73 shown to promote sleepiness

Novo Nordisk seeks Japanese approval for insulin detemir

Preclinical efficacy of targeting MTAP as an anticancer strategy

Novartis receives U.S. regulatory approval to acquire Chiron

Activation of Nrf2 pathway found to produce antitumorigenic effects in rat liver

Antiamyloidogenic compound also shown to induce neuritogenesis and neuronal differentiation

Recent patents reveal novel agents in early development for schizophrenia, depression, etc.

New treatments for urinary incontinence claimed in recent patents

Novel therapeutic agents for allergic disorders prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...